TRAXFirst Tracks Biotherapeutics Inc. Ordinary Shares
43.11USD-5.25%Mkt Cap: 1.54B $P/E: —3d ago
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a …
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap1.54B $
Enterprise Value1.33B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-163.71M $
Revenue/Share—
Last Price43.11 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees104
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-11.43
PEG—
EV/EBITDA-7.89
EV/Revenue—
P/S—
P/B8.78
EPS (TTM)-4.34
EPS (Forward)-3.66
52W Range
14.7981% of range49.91
52W High49.91 USD
52W Low14.79 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-41.80%
ROA-37.05%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-125.81M $
CapEx (TTM)358.00K $
FCF Margin—
FCF Yield—
Net Debt-163.69M $
Net Debt/EBITDA0.97
Balance Sheet
Debt/Equity0.04
Current Ratio14.28
Quick Ratio13.91
Book Value/Sh4.770 USD
Cash/Share4.702 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)69.44 USD
Upside (mean)+61.1%
Target Range55.00 USD – 95.00 USD
$55.00+61.1% to mean$95.00
# Analysts9
Ownership
Shares Out.35.73M
Float26.15M
Insiders8.74%
Institutions92.13%
Short Interest
Short Ratio4.0d
Short % Out.11.34%
Shares Short4.77M
Short (prev mo.)3.91M
Technical
SMA 5032.52 (+32.6%)
SMA 20026.14 (+64.9%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)865.68K
Avg Vol (10d)604.31K
Technical Indicators
RSI (14)56.1
MACD3.3002
MACD Signal4.3455
MACD Hist.-1.0453
BB Upper50.42 USD
BB Middle44.08 USD
BB Lower37.74 USD
BB Width28.78%
ATR (14)3.510 USD
Vol Ratio (20d)0.74x